MEDEXUS PHARMACEUTICALS INC (MDP.CA) Fundamental Analysis & Valuation

TSX:MDP • CA58410Q2036

Current stock price

3.14 CAD
+0.11 (+3.63%)
Last:

This MDP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. MDP.CA Profitability Analysis

1.1 Basic Checks

  • MDP had negative earnings in the past year.
  • MDP had a positive operating cash flow in the past year.
  • In multiple years MDP reported negative net income over the last 5 years.
  • In multiple years MDP reported negative operating cash flow during the last 5 years.
MDP.CA Yearly Net Income VS EBIT VS OCF VS FCFMDP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -0.18%, MDP is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
  • MDP's Return On Equity of -0.52% is fine compared to the rest of the industry. MDP outperforms 69.70% of its industry peers.
  • MDP's Return On Invested Capital of 3.02% is fine compared to the rest of the industry. MDP outperforms 72.73% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MDP is in line with the industry average of 8.53%.
  • The last Return On Invested Capital (3.02%) for MDP is well below the 3 year average (9.89%), which needs to be investigated, but indicates that MDP had better years and this may not be a problem.
Industry RankSector Rank
ROA -0.18%
ROE -0.52%
ROIC 3.02%
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
MDP.CA Yearly ROA, ROE, ROICMDP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Operating Margin of MDP (3.91%) is better than 75.76% of its industry peers.
  • MDP has a Gross Margin of 53.87%. This is amongst the best in the industry. MDP outperforms 81.82% of its industry peers.
  • In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
Industry RankSector Rank
OM 3.91%
PM (TTM) N/A
GM 53.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
MDP.CA Yearly Profit, Operating, Gross MarginsMDP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MDP.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDP is still creating some value.
  • MDP has more shares outstanding than it did 1 year ago.
  • MDP has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MDP has been reduced compared to a year ago.
MDP.CA Yearly Shares OutstandingMDP.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
MDP.CA Yearly Total Debt VS Total AssetsMDP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of 0.66, we must say that MDP is in the distress zone and has some risk of bankruptcy.
  • MDP has a better Altman-Z score (0.66) than 66.67% of its industry peers.
  • MDP has a debt to FCF ratio of 1.48. This is a very positive value and a sign of high solvency as it would only need 1.48 years to pay back of all of its debts.
  • MDP has a better Debt to FCF ratio (1.48) than 90.91% of its industry peers.
  • A Debt/Equity ratio of 0.35 indicates that MDP is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.35, MDP perfoms like the industry average, outperforming 51.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.48
Altman-Z 0.66
ROIC/WACC0.33
WACC9.27%
MDP.CA Yearly LT Debt VS Equity VS FCFMDP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 1.12 indicates that MDP should not have too much problems paying its short term obligations.
  • MDP has a Current ratio of 1.12. This is in the lower half of the industry: MDP underperforms 78.79% of its industry peers.
  • A Quick Ratio of 0.62 indicates that MDP may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.62, MDP is doing worse than 78.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.62
MDP.CA Yearly Current Assets VS Current LiabilitesMDP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDP.CA Growth Analysis

3.1 Past

  • The earnings per share for MDP have decreased strongly by -112.14% in the last year.
  • The Revenue has decreased by -9.23% in the past year.
  • The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%

3.2 Future

  • The Earnings Per Share is expected to grow by 53.29% on average over the next years. This is a very strong growth
  • MDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.80% yearly.
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDP.CA Yearly Revenue VS EstimatesMDP.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M
MDP.CA Yearly EPS VS EstimatesMDP.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

6

4. MDP.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDP. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 7.09, the valuation of MDP can be described as very cheap.
  • 87.88% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.83, MDP is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.09
MDP.CA Price Earnings VS Forward Price EarningsMDP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

  • 84.85% of the companies in the same industry are more expensive than MDP, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 90.91% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 4.31
EV/EBITDA 6.2
MDP.CA Per share dataMDP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • MDP's earnings are expected to grow with 109.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101%
EPS Next 3Y109.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDP.CA Dividend Analysis

5.1 Amount

  • No dividends for MDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDP.CA Fundamentals: All Metrics, Ratios and Statistics

MEDEXUS PHARMACEUTICALS INC

TSX:MDP (3/13/2026, 7:00:00 PM)

3.14

+0.11 (+3.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)N/A
Inst Owners0.65%
Inst Owner ChangeN/A
Ins Owners7.65%
Ins Owner ChangeN/A
Market Cap101.42M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.03 (123.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)11.09%
PT rev (3m)11.47%
EPS NQ rev (1m)50%
EPS NQ rev (3m)50%
EPS NY rev (1m)85.71%
EPS NY rev (3m)81.82%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.09
P/S 0.74
P/FCF 4.31
P/OCF 4.26
P/B 1.42
P/tB N/A
EV/EBITDA 6.2
EPS(TTM)-0.02
EYN/A
EPS(NY)0.44
Fwd EY14.1%
FCF(TTM)0.73
FCFY23.18%
OCF(TTM)0.74
OCFY23.46%
SpS4.22
BVpS2.22
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.18%
ROE -0.52%
ROCE 4.2%
ROIC 3.02%
ROICexc 3.61%
ROICexgc 107.26%
OM 3.91%
PM (TTM) N/A
GM 53.87%
FCFM 17.26%
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.48
Debt/EBITDA 1.33
Cap/Depr 2.1%
Cap/Sales 0.21%
Interest Coverage 1.57
Cash Conversion 127.65%
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 0.62
Altman-Z 0.66
F-Score5
WACC9.27%
ROIC/WACC0.33
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y44.59%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A

MEDEXUS PHARMACEUTICALS INC / MDP.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.


What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?

ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?

MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.


What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?

The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.